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Abstract There are two classes of an intracellular ‘modulator
protease’, calpain: ubiquitous and tissue-speci¢c. p94/calpain 3
is an example of the latter, predominantly expressed in muscle.
A defect in the p94 gene causes muscular dystrophy. Here we
report that human and mouse p94 genes have a possible novel
alternative promoter expressing p94 variants in all tissues ex-
amined including human lens epithelial cells. The possible pro-
moter region and the following novel exons overlap the 3P region
of the neutral K-glucosidase C gene. Unlike p94, the novel p94
variants expressed in COS7 cells do not undergo rapid autoly-
sis, suggesting basic functions di¡erent from p94.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Calpain is a Ca2þ-regulated intracellular ‘modulator pro-
tease’, which modulates cellular functions by limited and spe-
ci¢c proteolytic processing activity [1^5]. Calpain homologs
have been identi¢ed in most living organisms, and constitute
the ‘calpain superfamily’ [2]. Two representative well-charac-
terized members, the W- and m-calpains, or ‘conventional’
calpains, are ubiquitously expressed, and play important and
essential roles in cellular functions. The W- and m-calpains are
heterodimers consisting of a unique larger catalytic subunit
(WCL and mCL, respectively), and a common smaller regula-
tory subunit (30K).
Recent crystal structural analyses of calpain [6,7] have dem-
onstrated that mCL is composed of four functional domains
(see Fig. 1A), i.e. the N-terminal anchoring K-helix domain
(domain I), important for the regulation of activity and sub-
unit dissociation [8] ; the catalytic domain (II), which is divid-
ed into two subdomains in the absence of Ca2þ ; the C2-like
domain (III) ; and the 5-EF-hand (or penta-EF-hand [PEF])
domain (IV).
The discovery of p94 (also called calpain 3) in 1989 [9] led
to the concept that calpains are divided into two classes:
ubiquitous and tissue-speci¢c. p94 is the ¢rst and typical ex-
ample of the latter, and is predominantly expressed in skeletal
muscle. The whole primary structure of p94 is similar to those
of WCL and mCL, except for the p94-speci¢c sequences, NS,
IS1, and IS2 (see Fig. 1A) [9]. p94 has the following unique
characteristics, distinct from the other proteases, as well as
those of the conventional calpains: (i) p94 undergoes very
rapid, exhaustive, and apparently Ca2þ-independent autolysis
(half-life in vitro is less than 10 min) [10] ; (ii) inhibitors of the
conventional calpains, including calpastatin and ethylenedi-
amine tetraacetic acid (EDTA), have no e¡ect on p94 autol-
ysis [10] ; (iii) p94 associates with connectin (titin), the gigantic
¢lamentous molecule essential for myo¢brils [11,12]; and (iv)
a defect in the human p94 gene, CAPN3, is responsible for
limb-girdle muscular dystrophy type 2A (LGMD2A), indicat-
ing that p94 is indispensable for proper muscle function [13].
Several studies indicate that the loss of substrate-processing
activity of p94, but not hyperactivation or a defect in the
structural properties, causes LGMD2A [14^17].
Mouse Capn3 has an alternative promoter, which drives a
lens-speci¢c splicing variant of p94, Lp82 [18]. Lp82 proteol-
yses crystallins, and is involved in the molecular mechanisms
of rodent cataract formation [18,19]. It should be noted that
human CAPN3 has lost this variant during the course of
evolution [20].
Recently, we found that cyclin A is proteolysed to the more
stable fragment in the embryonic liver and other myeloid pro-
genitor cells [21]. Northern and Western blot analyses suggest
the involvement of p94 or its splice variants, which are ex-
pressed at very low levels. Although mRNA for p94 is de-
tected predominantly in skeletal muscle, there are several re-
ports showing small amounts of p94 transcripts in brain,
lymphocytes, and spleen [22^24]. Therefore, we performed
an extensive search for p94-related molecules in non-muscle
cells to elucidate the functions of CAPN3 in tissues other than
skeletal muscle. To our surprise, the newly identi¢ed mole-
cules utilize a novel alternative promoter of CAPN3/Capn3,
which drives ubiquitous expression through a novel initiation
exon, and not the authentic NS-encoding exon 1.
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Fig. 1. Schematic structures of p94-related molecules and their gene organizations. A: Schematic structures and the exon usage. Positions of the alternatively spliced exons and the recognition
sites of antibodies used in this study are indicated by lines with arrow heads and thick lines, respectively, on the p94 structure at the top. Mouse mLp82, rat rLp85, human hTp36, hTp31, and
hMp18 are from the database (AAC61764, AAC15423, BC003169, BG530497, and BC004883, respectively). B: Exon splicing schemes. Domain structures are indicated by di¡erent colors. Arrows
with numbers in the parentheses indicate positions of primers used in this study (see Table 1). C: Gene organization of the 3P part of GANC/Ganc and the 5P part of CAPN3/Capn3. The last
four exons of GANC/Ganc and the ¢rst 10/9 exons of CAPN3/Capn3 are shown with splicing patterns below. Red, dark blue, or magenta exons following the promoter boxes labeled ‘UP’,
‘SkmP’, or ‘LP’ are driven ubiquitously, skeletal muscle speci¢cally, or lens speci¢cally, respectively. Lengths of exons and introns are shown above or under them. Gray and other boxes corre-
spond to coding and non-coding regions, respectively. D: Amino acid sequences of the N-termini of calpains. Secondary structures determined for human m-calpain [7] are shown below. Closed
and open triangles indicate positions of introns inserted and the active site Cys, respectively. Residues conserved among at least ¢ve species are inverted.
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Fig. 1 (Continued).
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2. Materials and methods
2.1. Polymerase chain reaction (PCR) and primers
PCR was performed using Pfu (Stratagene Inc.) or ExTaq (Takara
Shuzo Inc.) DNA polymerases, and the human cDNA panels
(K1426-1, K1428 and K1420-1; Clontech Inc.) or ¢rst strand cDNAs
synthesized from mouse eye and human lens epithelial cell SRA01/04
[25] as templates. Primers used were listed in Table 1. PCR products
were separated by agarose gel electrophoresis and visualized with
ethidium bromide staining.
2.2. Construction of expression vectors for p94-related molecules
hUp84 and hUp49 cDNA fragments were ampli¢ed from human
spleen and resting CD8þ cDNAs (Clontech Inc.), respectively, by
PCR using Pfu DNA polymerase and primers hUpS2 and hp94Aex24.
mUp76/48 cDNA fragments were isolated from mouse spleen cDNA
using primers mUpS1 and hp94Aex24. These fragments were ligated
into pcDNA3.1-N-FLAG vector (a kind gift from Dr. Tatsuya Mae-
da, University of Tokyo) to express the proteins with an N-terminal
FLAG tag.
2.3. Cell culture and assays
COS7 cell culture, transfection, and detection of expressed pro-
teins by Western blotting were performed as previously described
[10,17].
3. Results and discussion
3.1. Identi¢cation of a novel isoform of mouse p94
Previously, we had observed shorter transcripts of the p94
gene in chicken spleen [24] and mouse erythroleukemia cells
(data not shown), in agreement with recent reports of non-
muscle expression of p94-related molecules [22,23]. To identify
the p94-related molecules in these cells, 5P rapid ampli¢cation
of cDNA ends was performed using a primer corresponding
to the protease domain of p94. One mouse cDNA fragment
was ampli¢ed that had a sequence corresponding to the pro-
tease domain, but the 5P upstream sequence di¡ered from that
of the ¢rst exon of either p94 or Lp82 (see Fig. 1B). A data-
base search revealed that this upstream sequence is identical
to the 3P part of the neutral K-glucosidase C gene (Ganc) [26].
The Ganc gene exists ca. 3.4 kb upstream from the ¢rst exon
of p94 (Fig. 1C). The 5P sequence of the newly identi¢ed p94-
related molecule (mUp76, where U stands for ‘ubiquitous’,
and p76 indicates its deduced molecular mass) corresponds
to all or part of the last four exons, exons 20^23, of Ganc
(Fig. 1C). The exon^intron junctions of these four exons
coincide with those of Ganc. The fourth junction, between
the fourth and ¢fth exons of mUp76, i.e. novel exon AX2
and p94 exon 2, which are 20 786 bp apart, also conforms
to the GT-AG rule. The open reading frame of mUp76 in
exon AX2, however, is distinct from that of exon 23 of
Ganc (Fig. 1C).
3.2. Identi¢cation of a human orthologue of mUp76 and other
splice variants
To exclude the possibility of arti¢cial ampli¢cation of a
‘chimeric’ cDNA of Capn3 and Ganc, an expressed sequence
tag (EST) database search was performed. The EST clone
AK097401 from human testis was identi¢ed, which has a
structure similar to that of the 5P part of mouse mUp76
(hUp49 in Fig. 1). Furthermore, using the human GANC se-
quence, a human orthologue of mUp76 was isolated from
spleen cDNA by PCR using primers hUpS1 and p94Aex7
(Table 1, (1) and (5) in Fig. 1B).
Several other alternative splicing variants were further iso-
lated, and are summarized in Fig. 1B. hUp12 uses a novel
exon (exon 2P) between exons 2 and 3 of p94, which results
in the production of a very short polypeptide of ca. 12 kDa.
Intron 12 of p94 is unspliced in hUp49, which, therefore, lacks
the C-terminal half of domain III and regions thereafter.
mUp48 contains a sequence from a novel exon (exon 12P)
between exons 12 and 13 of p94, which results in termination
within domain III with a short unique C-terminal sequence.
hUp84 lacks exon 15 of p94, whereas mUp76 lacks exons 6,
15, and 16.
In summary, a novel promoter region (‘UP’ in Fig. 1C) for
human and mouse CAPN3/Capn3 should exist in the 3P part
of GANC/Ganc, generating p94-like proteases (mUp76 and
hUp84) and their truncated forms (mUp48, hUp49, and
hUp12) with IS1 and/or all or a part of IS2 (Fig. 1B, depos-
ited in DDBJ under accession numbers AB117940^
AB117944). These possible novel promoter regions of both
mouse and human contain consensus sequences for the nu-
clear factor of activated T-cells (NF-AT, GGAAAA) and
CCAAT enhancer binding protein K (C/EBPK, TTGCNN-
AA). The presence of the C/EBPK binding site suggests that
the novel p94 promoters are under the control of C/EBPK,
and may explain why C/EBPK knockout mice did not show
p94-like cyclin A processing activity [21].
Overlapping genes are rather rare, if not non-existent, in
organisms with large genomes like mammals [27,28]. We
have previously reported an overlap between the mCL and
nCL-2/-2P genes, CAPN2 and CAPN8, in head-to-head orien-
tation [29]. At present, there is no evidence of a relationship
between CAPN3/Capn3 and GANC/Ganc, but it is possible
that both genes a¡ect one another’s transcription, at least in
part.
3.3. Structure of novel isoforms of p94
The newly identi¢ed p94 isoforms have truncated N-termi-
nal sequences compared with other calpains (Fig. 1D). They
are not only short but lack the N-terminal ‘WK(R/K)P’ motif,
Fig. 1 (Continued).
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highly conserved among calpain homologs [2]. The linker re-
gion connecting domains I and II is rather divergent among
calpains, has no secondary structure except for one short K-
helix (Fig. 1D, KII-1), and does not exist in the three-dimen-
sional structure of papain, which is very similar to that of the
calpain protease domain. Therefore, this region may be in-
volved in a function speci¢c to each calpain homolog. In
this sense, the divergent N-termini of hUp84 and mUp76 im-
ply speci¢c functions for these molecules.
In addition to the isoforms described above, the database
also contains several interesting cDNA sequences. As shown
in Fig. 1A and B, another novel initiation exon (AX3) exists
between exons 12 and 13 in ESTs mainly from human testis
(hTp36 and hTp31). AX3 is slightly di¡erent from exon 12P
found in mUp48. hTp36 and hTp31 have a structure comple-
mentary to that of hUp49. Previously, we have observed a
signi¢cant departure from Mendelian transmission of the
Capn33=3 allele [15]. It is possible that these testis-expressing
p94 isoforms, as well as mUp76 and mUp48, are involved in
this phenomenon. hMp18, which is strongly expressed in mel-
anoma cells (28 EST sequences were found in melanoma
cDNA), possesses another alternative initiation exon (AX4)
between exons 14 and 15. hMp18 contains only four and a
half EF-hand motifs. ALG-2, which has ¢ve EF-hands, was
reported to have anti-apoptotic functions when expressed in
cancer cells [30], suggesting a similar role for hMp18.
3.4. Expression pro¢le of novel isoforms of p94
The promoter of CAPN3/Capn3 that produces p94 (‘SkmP’
in Fig. 1C) is virtually skeletal muscle-speci¢c [31], and that
producing Lp82 (‘LP’) is lens-speci¢c [32]. Therefore, we ex-
amined the expression pro¢les of the newly identi¢ed variants
by PCR using primers corresponding to exons 32 and 5 (Ta-
ble 1, Fig. 1B). As shown in Fig. 2A, D and H, expression was
detected in all human tissues examined, as is the case for
ubiquitously expressed WCL (Fig. 2C, F and H). Mouse
cDNAs gave essentially the same results (data not shown).
These suggest basic and essential physiological roles of novel
isoforms of p94, like the conventional calpains. In mouse eye,
mUp76/48 was hardly detectable (Fig. 2G, lane 1), and, in-
stead, Lp82 was abundantly detected (lane 3) as previously
reported [32]. On the other hand, human lens epithelial cells,
SRA01/04 [25], in which Lp82 does not exist [20], express
hUp84/49 (Fig. 2H, lane 1). It is, therefore, suggested that,
analogously to an involvement of Lp82 in rodent cataract
formation, hUp84 and/or hUp49 play a role in human cata-
ract formation. These results indicate that the possible novel
promoter acts ubiquitously, unlike the promoters for p94 and
Lp82. Qualitatively, the levels of expression were much lower
than that of WCL. However, resting immune cells (Fig. 2A,
lanes 9^12) showed relatively abundant expression.
The location of GANC/CAPN3 (15q15.1) is implicated in
diabetes [33]. It is likely that the functions of p94 in skeletal
muscle are indirectly involved in the molecular mechanisms of
diabetes. Alternatively, ubiquitous hUp84/49/12 may play di-
rect roles in diabetes by, for example, modulating adipose cell
functions, which is also assumed for calpain 10 [34].
During preparation of this manuscript, De Tullio et al.
reported that circulating mononuclear blood cells express a
p94 isoform that lacks IS1 but contains NS and IS2 [23].
Thus, the expression of NS-containing isoforms was also ex-
amined. As shown in Fig. 2B, E and H, most tissues express
NS-containing isoforms except activated B- and T-cells (lanes
13^16), which is consistent with their report [23].
3.5. Expression of novel isoforms of p94 in COS7 cells
Next, to test whether the novel p94 isoforms are translated
into protein, they were expressed in COS7 cells. Western blot
analysis detected hUp84, mUp76, hUp49, and mUp48 at the
expected positions. Although the expressed protein amounts
were much lower than p94:C129S (data not shown), the same
amounts were detected for both wild type and the active site
Cys to Ser mutants (Fig. 3). Therefore, we concluded that
these isoforms do not undergo quick autolysis, unlike muscle
type p94 [10]. p94 without exon 15, which is identical to
hUp84 except for NS, showed considerable Ca2þ-independent
autolytic activity [14], indicating that the substitution of NS
with AX2 stabilizes p94 against autolysis. Our ¢ndings argue
that the novel p94 isoforms, with structures and expression
pro¢les divergent from those of the original p94, should be
recognized as an important part of the ubiquitous calpain
system.
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Table 1
Primers used in this study
Speci¢city Name Sequence (5PC3P) Position in Fig. 1B
Human Upa hUpS1 CATCTTCTGTGACTACCCAC (1)
Human Up hUpS2 GGAATGAGTTGGCAAATCAG (2)
Human p94 hp94Sex1 CCATCATTAGCCGCAATTTTCC (3)
Human Up/p94 hp94Aex5 CCTGTGAAGTCCTCCATGGC (4)
Human Up/p94 hp94Aex7 TATAAGCTTCTCATCCAGCCCCGTGAC (5)
Human/mouse Up/p94 hp94Aex24 GGACTAGTGGTTCAGGCATACATGGT (6)
Mouse Up mUpS1 GGATCCGTAGAGCTCAGCCTGCAGCTT (7)
Mouse Up mUpS2 ATTGTGCCGAAACATCTGCC (8)
Mouse p94 mp94Sex1 CGATCATCGGTGTGAAAGAG (9)
Mouse Lp82 mLp82S1 AGTGCCTCTTTGAAGACCGT (10)
Mouse Up/p94/Lp82 mp94Aex4 CAGACAGTCGTCAATGACCA (11)
Mouse Up/p94/Lp82 mp94Aex8 GCACCAACTTCACCTTCTCA (12)
Human/mouse WCL WCLS1 CGTGACTTCTTCCTGGCCAA ^
Human/mouse WCL WCLA1 AGGATGTTGAACTCCACCAG ^
aUp stands for novel isoforms of p94, hUp84/49/12 for human and mUp76/48 for mouse.
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Fig. 3. Novel p94 isoforms are stable when expressed in COS7 cells.
Wild type (lanes 2, 4, 7, and 9) or CysCSer mutant (C42S for
hUp84/49 (lanes 3 and 5) and C53S for mUp76/48 (lanes 8 and 10))
of hUp84 (lanes 2 and 3), mUp76 (lanes 4 and 5), hUp49 (lanes 7
and 8), or mUp48 (lanes 9 and 10) were expressed in COS7 cells,
and detected by p94-speci¢c anti-pIS2 antiserum (lanes 1^5), which
recognizes the peptide sequence between domains III and IV
(NTISVDRPVKKKKNKPIIFV), or monoclonal antibody 12A2
(Novacastra Lab. Ltd.) (lanes 6^10), which recognizes the peptide
sequence around active site Asn in domain IIb (RLRNPWG-
QVEWNGSWS) (see Fig. 1A). Open arrowheads indicate expressed
proteins. Lanes 1 and 6, lysates of cells transfected with pcDNA3.1-
N-FLAG vector.
6
Fig. 2. Expression of novel isoforms of p94 detected by reverse transcription (RT)-PCR. PCR was performed using primers (1) and (4) (see Ta-
ble 1 and Fig. 1B) speci¢c to hUp84/49/12 (A and D, all lanes, and H, lane 1); (3) and (4) speci¢c to human p94 (B and E, all lanes, and H,
lane 2); WCLS1 and WCLA1 speci¢c to human/mouse WCL (C and F, all lanes, G, lane 2, and H, lane 3); (8) and (11) speci¢c for mouse
mUp76/48 (G, lane 1); and (10) and (12) speci¢c to mouse Lp82 (G, lane 3). In A, D and H, 903-bp and 625-bp bands correspond to hUp12
with exon 2P and pUp84/49 without exon 2P, respectively. Other bands also correspond to p94 variants, judging from Southern blot analyses
with p94 cDNA as a probe (data not shown), although the precise structures have not yet been determined. Template cDNAs used for PCR
are as follows: Lanes for A^C: 1, spleen; 2, lymph node; 3, thymus; 4, tonsil ; 5, leukocyte, peripheral blood; 6, bone marrow; 7, fetal liver;
8, mononuclear cells (monocytes, T-, and B-cells); 9, resting CD8þ (suppressor and cytotoxic T-cells); 10, resting CD4þ (helper and inducer
T-cells); 11, resting CD14þ (monocytes) ; 12, resting CD19þ (B-cells) ; 13, activated CD19þ ; 14, activated mononuclear cells ; 15, activated
CD4þ ; 16, activated CD8þ. Lanes for D^F: 1, heart; 2, brain; 3, placenta; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, pancreas. Lanes
for G: 1^3, mouse eye. Lanes for H: 1^3, human lens epithelial cell SRA01/04 [25]. Lanes labeled by letters starting with P and N indicate
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